Wulfran Cacheux

IKZF2-ERBB4 gene fusion leads to ERBB4 overexpression in Anal Squamous Cell Carcinoma but with no benefit for ERBB4 inhibition

Richon Sophie, Lamontagne Julien, Briaux Adrien, Sophie Vacher et autres

Abstract Anal squamous cell carcinoma (ASCC) is a rare tumour, but with increasing incidence for local and metastatic tumours. Current therapy is based on chemoradiotherapy, associated with immunotherapy in advanced stages, with frequent side effects, poor results in advanced stages and recurrence. …

fr (code pays fourni par la source)

47P Does metastatic site influence the outcome in colorectal cancer patients treated with regorafenib? Insights from the phase II randomized study SOREGATT - PRODIGE 68 - UCGI 38

C. Smolenschi, M-L. Tanguy, Méher Ben Abdelghani, Aurélie Parzy et autres

fr, be (code pays fourni par la source)

3O PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)

Michel Pierre Ducreux, Méher Ben Abdelghani, David Tougeron, O. Bouche et autres

fr, be, lu (code pays fourni par la source)

Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resection

Abderaouf Hamza, Julien Masliah‐Planchon, Cindy Neuzillet, Jérémie H. Lefèvre et autres

Abstract The management of anal squamous cell carcinoma (ASCC) has yet to experience the transformative impact of precision medicine. Conducting genomic analyses may uncover novel prognostic biomarkers and offer potential directions for the development of targeted therapies. To that end, we assessed …

fr, it (code pays fourni par la source)

Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

Maud Kamal, Sonia Lameiras, Marc Deloger, Adeline Morel et autres

The original version of this article contained an error in an affiliation. Upon careful review of the paper, the authors noticed that the affiliation for Goran Malenkovic was not written correctly. The authors only submitted the following affiliation Gynecologic Oncology Department Clinic …

fr, nl, rs, md, ro, de, hu, ie, ch (code pays fourni par la source)

Data from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Abstract Development of targeted therapeutics required translationally relevant preclinical models with well-characterized cancer genome alterations. Here, by studying 52 colorectal patient-derived tumor xenografts (PDX), we examined key molecular alterations of the IGF2–PI3K and ERBB–RAS pathways and response to cetuximab. PDX molecular data …

Supplementary Table 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations in KRAS/BRAF/NRA S wild-type xenografts, according to their response to cetuximab. Tumors were considered to be amplified if the gene copy number was >3. Gene overexpression is defined by an expression superior to average in all PDX panel + 1 …

Supplementary Figure 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations of IGF2-PI3K pathway in MSS human colorectal cancer cell lines. A. Gene expression, gene copy number and mutation data provided by the Cancer Cell Line Encyclopedia were studied in the 36 MSS cell lines out of the cohort of the …

Supplementary Figure 2 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Example of 2 PDXs treated with cetuximab (one red arrow for each injection).

Supplementary Figure 2 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Example of 2 PDXs treated with cetuximab (one red arrow for each injection).

Supplementary Figure 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations of IGF2-PI3K pathway in MSS human colorectal cancer cell lines. A. Gene expression, gene copy number and mutation data provided by the Cancer Cell Line Encyclopedia were studied in the 36 MSS cell lines out of the cohort of the …

Supplementary Table 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations in KRAS/BRAF/NRA S wild-type xenografts, according to their response to cetuximab. Tumors were considered to be amplified if the gene copy number was >3. Gene overexpression is defined by an expression superior to average in all PDX panel + 1 …